Hunan Fangsheng Pharmaceutical Co., Ltd. (603998.SS)
CNY 9.6
(0.0%)
CNY 9.6
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 186.82 Million CNY | -34.64% |
| 2022 | 285.85 Million CNY | 308.13% |
| 2021 | 70.04 Million CNY | 9.79% |
| 2020 | 63.79 Million CNY | -19.16% |
| 2019 | 78.91 Million CNY | 8.11% |
| 2018 | 72.99 Million CNY | 22.31% |
| 2017 | 59.68 Million CNY | -14.44% |
| 2016 | 69.75 Million CNY | -23.07% |
| 2015 | 90.67 Million CNY | 11.96% |
| 2014 | 80.99 Million CNY | 10.29% |
| 2013 | 73.43 Million CNY | 11.07% |
| 2012 | 66.11 Million CNY | 27.45% |
| 2011 | 51.87 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 70.19 Million CNY | 56.59% |
| 2024 Q2 | 66.65 Million CNY | -5.04% |
| 2024 Q3 | 91.29 Million CNY | 36.97% |
| 2023 Q3 | 35.28 Million CNY | -17.81% |
| 2023 Q1 | 63.78 Million CNY | 78.98% |
| 2023 Q2 | 42.92 Million CNY | -32.7% |
| 2023 FY | 186.82 Million CNY | -34.64% |
| 2023 Q4 | 44.82 Million CNY | 27.04% |
| 2022 FY | 285.85 Million CNY | 308.13% |
| 2022 Q4 | 35.63 Million CNY | -81.84% |
| 2022 Q3 | 196.26 Million CNY | 993.56% |
| 2022 Q2 | 17.94 Million CNY | -47.54% |
| 2022 Q1 | 34.21 Million CNY | 333.39% |
| 2021 FY | 70.04 Million CNY | 9.79% |
| 2021 Q2 | 18.85 Million CNY | -19.83% |
| 2021 Q4 | 7.89 Million CNY | -60.05% |
| 2021 Q3 | 19.76 Million CNY | 4.79% |
| 2021 Q1 | 23.52 Million CNY | 596.24% |
| 2020 Q3 | 22.09 Million CNY | 18.64% |
| 2020 Q2 | 18.62 Million CNY | -5.47% |
| 2020 Q1 | 19.7 Million CNY | 133.08% |
| 2020 FY | 63.79 Million CNY | -19.16% |
| 2020 Q4 | 3.37 Million CNY | -84.71% |
| 2019 FY | 78.91 Million CNY | 8.11% |
| 2019 Q1 | 23.92 Million CNY | 98.25% |
| 2019 Q2 | 29.96 Million CNY | 25.26% |
| 2019 Q3 | 16.57 Million CNY | -44.7% |
| 2019 Q4 | 8.45 Million CNY | -48.99% |
| 2018 Q2 | 22.98 Million CNY | -1.64% |
| 2018 FY | 72.99 Million CNY | 22.31% |
| 2018 Q4 | 12.06 Million CNY | -17.22% |
| 2018 Q3 | 14.57 Million CNY | -36.58% |
| 2018 Q1 | 23.36 Million CNY | 248.32% |
| 2017 Q2 | 28.49 Million CNY | 59.93% |
| 2017 Q3 | 29.11 Million CNY | 2.16% |
| 2017 Q4 | -15.75 Million CNY | -154.11% |
| 2017 FY | 59.68 Million CNY | -14.44% |
| 2017 Q1 | 17.81 Million CNY | 38.95% |
| 2016 Q4 | 12.82 Million CNY | -32.88% |
| 2016 Q3 | 19.1 Million CNY | -13.31% |
| 2016 FY | 69.75 Million CNY | -23.07% |
| 2016 Q1 | 15.78 Million CNY | -11.62% |
| 2016 Q2 | 22.03 Million CNY | 39.62% |
| 2015 Q2 | 26.96 Million CNY | 30.15% |
| 2015 Q1 | 20.71 Million CNY | 16.91% |
| 2015 FY | 90.67 Million CNY | 11.96% |
| 2015 Q4 | 17.86 Million CNY | -28.96% |
| 2015 Q3 | 25.14 Million CNY | -6.74% |
| 2014 Q3 | 20.88 Million CNY | -29.75% |
| 2014 Q1 | 12.65 Million CNY | -39.37% |
| 2014 FY | 80.99 Million CNY | 10.29% |
| 2014 Q2 | 29.73 Million CNY | 134.98% |
| 2014 Q4 | 17.71 Million CNY | -15.18% |
| 2013 Q4 | 20.86 Million CNY | 5.39% |
| 2013 Q3 | 19.8 Million CNY | 0.0% |
| 2013 FY | 73.43 Million CNY | 11.07% |
| 2012 FY | 66.11 Million CNY | 27.45% |
| 2011 FY | 51.87 Million CNY | 0.0% |